The previously mentioned currently recruiting phase 1b/2 study investigating biomarker-based treatment of AML also includes an Ivosidenib arm for those patients with IDH1 mutations (ClinicalTrials.gov NCT03013998). This evidence concerns the gene IDH1 and acute myeloid leukemia.